The U.S. Food and Drug Administration approved Evofem Biosciences Inc.’s Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

Merck is spinning off products from the company’s Women’s Health, Legacy Brands and Biosimilars businesses.

Amag Pharmaceuticals Inc. said the company would divest two of women’s health products, after the drugmaker conducted a strategic review under pressure from hedge fund Caligan Partners.

Apple Inc. launched an app that will let users of the company’s devices to enroll in three health studies, allowing them to share health-related data for medical research.

The U.S. Food and Drug Administration approved South African drugmaker Aspen Pharmacare’s hydroxyprogesterone caproate (HPC), which is used to prevent preterm birth in pregnant women.

The Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.

Older women who take supplements with high doses of vitamins B6 and B12 may be more likely than their counterparts who do not to experience hip fractures, a U.S. study suggests.

Allergan Plc forecast 2019 revenue below expectations on looming competition for some of the company’s top drugs, and shelved plans to sell the women’s health business.

Allergan Plc expressed disappointment in early offers from potential buyers for business units that the company has been trying to sell, with shares falling more than 6 percent.

Allergan plans to sell off both businesses as the company’s CEO works to end a steep slide in the drugmaker’s share price.